A+ Science AB

Merck Life Science A/S

Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”

With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.

A food-based strategy to stop gut infections early

Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier b...

We are expanding our English-language coverage

Over a period of four weeks, one of Life Science Sweden's regular daily newsletters is being published entirely in English. The aim is to meet increasing demand...

Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”

The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a r...

A healthy society requires more than a new pill

Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change

Dying man saved by artificial lung system

An external artificial lung system kept a critically ill man alive for two days until he could undergo a lung transplant. In the longer term, researchers hope t...

“BioArctic is Leqembi, but also much more”

What once began as a small Swedish biotech company has grown into a fully fledged pharmaceutical company with global reach. At the helm is Gunilla Osswald, who ...

Gothenburg-based Anyo Labs gains ground in the AI race

In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug develop...

Björn Arvidsson: ”As uncertainty grows, clarity becomes a strength”

Sweden has all the prerequisites to be a strong life science nation. But in a time of geopolitical tension, shorter value chains and growing demands for resilie...

“Ozempic babies” – myth or reality?

Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.

Atrogi on its challenger to GLP-1: “Now we are stepping forward”

A new approach to treating type 2 diabetes and obesity is taking shape in a laboratory just a stone’s throw from the Karolinska Institute. At Atrogi, researcher...

“Access to capital increases when there’s an exit”

It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee William...

Southern Swedish company Aqilion develops drug for eosinophilic esophagitis

When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...

Sprint Bioscience builds the molecules that will become new medicines

In Sprint Bioscience’s laboratory in Flemingsberg, Huddinge, molecules are being created that no one has ever built before. The company specializes in preclinic...

Fourteen US-based top researchers recruited to Sweden

Sweden has set its sights on America’s top scholars – and it seems to work. By the end of 2025, fourteen leading U.S.-based researchers had already been won ove...

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how t...

Thermo Fisher Expands in Sweden – “We Are Sending a Clear Message”

The American life science giant Thermo Fisher Scientific has inaugurated a new distribution center in Uppsala. “By investing in increasing our capacity as well ...

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Webinar: Enhancing Assay Sensitivity with Signal Amplification in a Microfluidic Assay

19 MARS 2026: Lyssna på vår gästtalare, Dr. Linda Klauss från Gyros Protein Technologies, när hon håller i ett exklusivt webbinarium där vi visar hur kombinatio...

“We develop vaccines no one else is developing”

Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute va...